Summary
Edwards Lifesciences Corporation (EW) filed an 8-K on October 25, 2016, primarily to announce its financial results for the third quarter of 2016. This filing incorporates by reference a press release dated October 25, 2016, which details the company's performance during the quarter. Investors should refer to this press release for specific financial metrics, revenue figures, earnings per share, and any forward-looking guidance provided by the company. The information provided in this 8-K is crucial for understanding the company's operational and financial standing as of the reporting date. While the 8-K itself is brief, the accompanying press release contains the substantive details of the Q3 2016 financial results. Investors are advised to examine the press release for commentary on key business segments, significant achievements, and any strategic updates that may impact future performance. It's important to note that the information furnished under Item 2.02 is not considered 'filed' for purposes of the Securities Exchange Act of 1934, meaning it doesn't carry the same legal implications as officially filed financial statements.
Key Highlights
- 1Edwards Lifesciences announced its third quarter 2016 financial results via a press release furnished with the 8-K filing.
- 2The filing date was October 25, 2016, and the event date was October 24, 2016, indicating a near real-time disclosure of results.
- 3The primary content of the filing is the press release detailing Q3 2016 financial performance.
- 4Investors can find specific financial data, revenue, and EPS figures within the referenced press release (Exhibit 99.1).
- 5The filing serves as official notification of the quarterly earnings release to the market.
- 6Information furnished under Item 2.02 is not deemed 'filed' under the Securities Exchange Act of 1934.